LOW-DOSE TAMOXIFEN: A New Clinical Trial Could Transform Breast Cancer Treatment
A New Era in Hormone Therapy?
Tamoxifen has been a cornerstone of hormone therapy for breast cancer for decades. By blocking estrogen receptors in breast tissue, it helps prevent recurrence in women with hormone receptor-positive breast cancer.
However, standard full-dose tamoxifen — and aromatase inhibitors like anastrozole, letrozole, and exemestane — often bring significant side effects that impact daily life, including:
- Osteoporosis and fractures
- Blood clots and stroke risk
- Endometrial cancer
- Severe joint pain
- Emotional, sexual, and quality-of-life impacts
Because of these side effects, many women struggle to stay on their medication for the full recommended duration — putting them at a higher risk of cancer recurrence.
Introducing a New Clinical Trial: Low-Dose Tamoxifen
What if there was a safer option?
A groundbreaking Phase III clinical trial is now underway, testing if low-dose tamoxifen, taken every other day, could provide the same life-saving protection — with far fewer side effects.
About the Clinical Trial (NCT06671912)
Eligibility: Postmenopausal women with hormone-positive, HER2-negative early-stage breast cancer.
Design: Patients are randomized to either standard hormone therapy or low-dose tamoxifen.
Duration: Treatment lasts up to 5 years, with an additional 10 years of follow-up.
Focus: The study will compare recurrence rates, side effects, quality of life, medication adherence, and survival between groups.
Why This Trial Matters
This trial could change the future of hormone-positive breast cancer care by:
- Offering a lower-risk alternative
- Improving quality of life for survivors
- Boosting medication adherence
- Potentially maintaining equivalent protection against recurrence
- Less Medication. Fewer Side Effects. Same Life-Saving Protection?
If successful, low-dose tamoxifen could become a powerful new option for thousands of women — allowing them to stay on their life-saving medication with fewer hardships.
You may be able to participate in this important study.
To learn more or check eligibility, visit ClinicalTrials.gov and search for NCT06671912 — or speak with your oncologist.
Special Thanks
Thank you to Dr. Barry Rosen, Breast Surgical Oncologist and Senior Medical Advisor for Learn Look Locate, for sharing this incredible advancement with our community. This truly could be a game changer for so many women struggling with the side effects of tamoxifen.
Share This Story, Choose Your Platform!
